Trading of Global Depositary Receipts (GDRs) for Beximco Pharmaceuticals Limited, one of Bangladesh’s largest drug manufacturers, is set to be suspended on the London Stock Exchange (LSE) starting from January 2, 2026.

The suspension comes after the company failed to publish its audited financial reports for the fiscal year ending June 30, 2024–25 within the mandatory time frame.

According to a disclosure on the LSE website, Beximco Pharma was unable to release its final annual results by the December 31, 2025 deadline required under the London Stock Exchange’s Alternative Investment Market (AIM). Consequently, the exchange is moving to temporarily halt the trading of the company’s GDRs.

The company cited ongoing legal complexities as the primary reason for the delay. The dispute involves a decision by the Bangladesh Securities and Exchange Commission (BSEC) to appoint nine additional independent directors to Beximco Pharma's board following the fall of regime in August 2024.

Beximco Pharma challenged this appointment in the High Court, and the matter remains sub-judice. The company stated that the Board of Directors cannot approve the financial reports until the legal status of the board is finalized.

Due to the current High Court recess and bench reconstitutions, the case must be heard afresh. A verdict is not expected until at least January 2026, causing a stalemate in the approval process.

REVIVAL Group to reopen BEXIMCO Textile, restoring 25,000 jobs

While trading will be paused in London, Beximco Pharma clarified that its shares will continue to trade normally on the Dhaka Stock Exchange (DSE) and the Chittagong Stock Exchange (CSE) in Bangladesh.

The company also assured investors that it would continue to provide all necessary disclosures in accordance with AIM rules throughout the suspension period.